Explore

Trendline Trendline
Infex Therapeutics Advances in Bronchiectasis Treatment with Trial Success

Infex Therapeutics Advances in Bronchiectasis Treatment with Trial Success

Infex Therapeutics Advances in Bronchiectasis Treatment with Trial Success
Trendline Trendline
Viking Therapeutics to Present at Major Investor Conferences in June

Viking Therapeutics to Present at Major Investor Conferences in June

Viking Therapeutics to Present at Major Investor Conferences in June
Trendline Trendline
Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results

Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results

Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results
Trendline Trendline
FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise
Trendline Trendline
Viking Therapeutics to Present at June 2026 Investor Conferences, Showcasing Metabolic Disorder Therapies

Viking Therapeutics to Present at June 2026 Investor Conferences, Showcasing Metabolic Disorder Therapies

Viking Therapeutics to Present at June 2026 Investor Conferences, Showcasing Metabolic Disorder Therapies
Trendline Trendline
Parabilis Medicines Files for IPO to Fund Cancer Drug Trials

Parabilis Medicines Files for IPO to Fund Cancer Drug Trials

Parabilis Medicines Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development
Trendline Trendline
Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status
Trendline Trendline
Daiichi Sankyo Faces Challenges in Antibody-Drug Conjugate Market Amid Setbacks

Daiichi Sankyo Faces Challenges in Antibody-Drug Conjugate Market Amid Setbacks

Daiichi Sankyo Faces Challenges in Antibody-Drug Conjugate Market Amid Setbacks